Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Jack

Showing results (81-90 of 99) with videos related to

Pageof 10
Sort By:
Blood|July 29, 2006
Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trialMarinus H J van Oers, Richard Klasa, Robert E Marcus, et al.
Lancet (London, England)|April 26, 2013
Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cyclesDavid Cunningham, Eliza A Hawkes, Andrew Jack, et al.
Haematologica|November 28, 2015
The addition of rituximab to fludarabine and cyclophosphamide chemotherapy results in a significant improvement in overall survival in patients with newly diagnosed mantle cell lymphoma: results of a randomized UK National Cancer Research Institute trialSimon Rule, Paul Smith, Peter W M Johnson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2009
Randomized comparison of the stanford V regimen and ABVD in the treatment of advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244Peter J Hoskin, Lisa Lowry, Alan Horwich, et al.
The Journal of Molecular Diagnostics : JMD|July 14, 2015
Somatic Mutation Screening Using Archival Formalin-Fixed, Paraffin-Embedded Tissues by Fluidigm Multiplex PCR and Illumina SequencingMing Wang, Leire Escudero-Ibarz, Sarah Moody, et al.
Blood|March 29, 2007
Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph)Lindsay M Morton, Jennifer J Turner, James R Cerhan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 28, 2011
The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL studyCatherine Thieblemont, Josette Briere, Nicolas Mounier, et al.
The Lancet. Oncology|March 8, 2014
Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trialKirit M Ardeshna, Wendi Qian, Paul Smith, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 9, 2013
Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 Randomized StudyEmanuele Zucca, Annarita Conconi, Daniele Laszlo, et al.
British Journal of Haematology|August 2, 2016
Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) in the management of primary mediastinal B-cell lymphoma: a subgroup analysis of the UK NCRI R-CHOP 14 versus 21 trialMary Gleeson, Eliza A Hawkes, David Cunningham, et al.
Pageof 10

Showing results (81-90 of 99) with videos related to

Sort By:
Pageof 10
Blood|July 29, 2006
Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trialMarinus H J van Oers, Richard Klasa, Robert E Marcus, et al.
Lancet (London, England)|April 26, 2013
Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cyclesDavid Cunningham, Eliza A Hawkes, Andrew Jack, et al.
Haematologica|November 28, 2015
The addition of rituximab to fludarabine and cyclophosphamide chemotherapy results in a significant improvement in overall survival in patients with newly diagnosed mantle cell lymphoma: results of a randomized UK National Cancer Research Institute trialSimon Rule, Paul Smith, Peter W M Johnson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2009
Randomized comparison of the stanford V regimen and ABVD in the treatment of advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244Peter J Hoskin, Lisa Lowry, Alan Horwich, et al.
The Journal of Molecular Diagnostics : JMD|July 14, 2015
Somatic Mutation Screening Using Archival Formalin-Fixed, Paraffin-Embedded Tissues by Fluidigm Multiplex PCR and Illumina SequencingMing Wang, Leire Escudero-Ibarz, Sarah Moody, et al.
Blood|March 29, 2007
Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph)Lindsay M Morton, Jennifer J Turner, James R Cerhan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 28, 2011
The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL studyCatherine Thieblemont, Josette Briere, Nicolas Mounier, et al.
The Lancet. Oncology|March 8, 2014
Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trialKirit M Ardeshna, Wendi Qian, Paul Smith, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 9, 2013
Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 Randomized StudyEmanuele Zucca, Annarita Conconi, Daniele Laszlo, et al.
British Journal of Haematology|August 2, 2016
Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) in the management of primary mediastinal B-cell lymphoma: a subgroup analysis of the UK NCRI R-CHOP 14 versus 21 trialMary Gleeson, Eliza A Hawkes, David Cunningham, et al.
Pageof 10